RSS-Feed abonnieren
DOI: 10.1055/s-0029-1245567
© Georg Thieme Verlag KG Stuttgart · New York
Endoskopische Prozeduren bei Patienten unter antithrombotischer Medikation – Risiken und praktisches Vorgehen
Endoscopic Procedures for Patients on Antithrombotic Medication – Risks and MethodsPublikationsverlauf
Manuskript eingetroffen: 11.3.2010
Manuskript akzeptiert: 24.6.2010
Publikationsdatum:
30. September 2010 (online)

Zusammenfassung
In die Entscheidung, wie mit einer antithrombotischen Therapie umzugehen ist, wenn eine endoskopische Intervention im Bereich des Gastrointestinaltrakts ansteht, geht sowohl das Blutungsrisiko der Maßnahme als auch das Risiko thrombembolischer Komplikationen bei Pausieren der Medikation ein. Das Blutungsrisiko endoskopischer Maßnahmen ohne absehbare Eröffnung der Blutbahn und bei endoskopischen Biopsien ist vernachlässigbar, auch bei oraler Antikoagulation. Diese muss daher nur pausiert werden, wenn blutungsgefährdete Interventionen wie Polypektomie, EPT o. Ä. anstehen. Bei hohem Risiko für thrombembolische Komplikationen wie Kunstklappe in Mitralposition oder Vorhofflimmern mit Risikofaktoren muss passager auf kürzer wirksame und damit besser steuerbare Antikoagulanzien gewechselt werden („Bridging”). Bei Therapie mit Plättchenfunktionshemmern und niedrigem Blutungsrisiko inkl. Biopsie bestehen keine Bedenken gegen den Eingriff. Vor unaufschiebbaren Eingriffen mit hohem Blutungsrisiko soll Clopidogrel nach Rücksprache mit dem Kardiologen für eine Woche pausiert werden. Für die Koloskopie z. B. in Form der Screening-Koloskopie bestehen 2 Optionen: 1. Pausieren einer oralen Antikoagulation (ggf. mit Bridging) bzw. Clopidogrelmedikation zur Koloskopie, 2. Weiterführen der antithrombotischen Medikation mit erneuter elektiver Endoskopie zur Polypektomie bei reduzierter antithrombotischer Medikation, wenn Polypen, die nicht durch Biopsie entfernt werden konnten, entdeckt wurden. Die Entscheidung zwischen diesen Optionen muss individuell fallen.
Abstract
The decision how to handle an antithrombotic treatment when an intervention during GI endoscopy is planned is influenced both by the risk of bleeding and by the thomboembolic risk when treatment is suspended. The risk of bleeding is negligible even when on oral anticoagulants in diagnostic procedures with standard forceps biopsies. Oral anticoagulation has to be stopped, however, when planning invasive procedures such as polypectomy or EPT. In the case of patients with a high risk of thromboembolic complications such as artificial valves in mitral position or atrial fibrillation with risk factors, one has to temporarily switch to anticoagulants with shorter action (”bridging”). Treatment with inhibitors of platelet function does not preclude procedures with a low risk of bleeding including forceps biopsy. Urgent procedures with a high risk of bleeding should be performed after stopping clopidogrel one week previously but only after consultation with the treating cardiologist. In the case of colonoscopy, in particular as a screening procedure, there are two options: 1) stopping oral anticoagulation (with or without bridging) or clopidogrel, respectively, or 2) continuing antithrombotic treatment and performing a second elective endoscopy for polypectomy with tapered antithrombotic medication if polyps are found which are not amenable to resection by biopsy forceps. The choice between these two options has to be made individually.
Schlüsselwörter
gastrointestinale Blutung - Endoskopie - Blutgerinnung
Key words
gastrointestinal bleeding - endoscopy - coagulation
Literatur
- 1
Scharf R E.
Management of bleeding in patients using antithrombotic agents. Prediction, prevention,
protection and problem-oriented intervention.
Hämostaseologie.
2009;
29
388-398
MissingFormLabel
- 2
Burger W, Chemnitius J M, Kneissl D et al.
Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after
its perioperative withdrawal versus bleeding risks with ist continuation – review
and meta-analysis.
J Intern Med.
2005;
257
399-414
MissingFormLabel
- 3
Douketis J D, Berger P B, Dunn A S et al.
The perioperative management of antithrombotic therapy: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008;
133
299S-339S
MissingFormLabel
- 4
Rosenfeldt M T, Haverkamp W, Trappe R et al.
Diagnostic and therapeutic management of patients receiving antithrombotic drugs:
what to heed?.
Dtsch Med Wochenschr.
2006;
131
982-986
MissingFormLabel
- 5
Bowles C J, Leicester R, Romaya C et al.
A prospective study of colonoscopy practice in the UK today: are we adequately prepared
for national colorectal cancer screening tomorrow?.
Gut.
2004;
53
277-283
MissingFormLabel
- 6
Gibbs D H, Opelka F G, Beck D E et al.
Postpolypectomy colonic hemorrhage.
Dis Colon Rectum.
1996;
39
806-810
MissingFormLabel
- 7
Rosen L, Bub D S, Reed 3rd
J F et al.
Hemorrhage following colonoscopic polypectomy.
Dis Colon Rectum.
1993;
36
1126-1131
MissingFormLabel
- 8
Shiffman M L, Farrel M T, Yee Y S.
Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin
or other NSAIDS.
Gastrointest Endosc.
1994;
40
458-462
MissingFormLabel
- 9
Sieg A, Hachmoeller-Eisenbach U, Eisenbach T.
Prospective evaluation of complications in outpatient GI endoscopy: a survey among
German gastroenterologists.
Gastrointest Endosc.
2001;
53
620-627
MissingFormLabel
- 10
Wexner S D, Garbus J E, Singh J J et al.
A prospective analysis of 13,580 colonoscopies. Reevaluation of credentialing guidelines.
Surg Endosc.
2001;
15
251-261
MissingFormLabel
- 11
Yousfi M, Gostout C J, Baron T H et al.
Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin.
Am J Gastroenterol.
2004;
99
1785-1789
MissingFormLabel
- 12
Cotton P B, Lehman G, Vennes J et al.
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
Gastrointest Endosc.
1991;
37
383-393
MissingFormLabel
- 13
Freeman M L, Nelson D B, Sherman S et al.
Complications of endoscopic biliary sphincterotomy.
N Engl J Med.
1996;
335
909-918
MissingFormLabel
- 14
Masci E, Toti G, Mariani A et al.
Complications of diagnostic and therapeutic ERCP: a prospective multicenter study.
Am J Gastroenterol.
2001;
96
417-423
MissingFormLabel
- 15
Nelson D B, Freeman M L.
Major hemorrhage from endoscopic sphincterotomy: risk factor analysis.
J Clin Gastroenterol.
1994;
19
283-287
MissingFormLabel
- 16
Vaira D, D’Anna L, Ainley C et al.
Endoscopic sphincterotomy in 1000 consecutive patients.
Lancet.
1989;
2
431-434
MissingFormLabel
- 17
Wang P, Li Z S, Liu F et al.
Risk factors for ERCP-related complications: a prospective multicenter study.
Am J Gastroenterol.
2009;
104
31-40
MissingFormLabel
- 18
Ono S, Fujishiro M, Niimi K et al.
Technical feasibility of endoscopic submucosal dissection for early gastric cancer
in patients taking anti-coagulants or anti-platelet agents.
J Gastroenterol.
2009;
44
1185-1189
MissingFormLabel
- 19
Neale J C, Goulden J W, Allan S G et al.
Esophageal stents in malignant dysphagia: a two-edged sword?.
J Palliat Care.
2004;
20
28-31
MissingFormLabel
- 20
Wang M Q, Sze D Y, Wang Z P et al.
Delayed complications after esophageal stent placement for treatment of malignant
esophageal obstructions and esophagorespiratory fistulas.
J Vasc Interv Radiol.
2001;
12
465-474
MissingFormLabel
- 21
Luman W, Kwek K R, Loi K L et al.
Percutaneous endoscopic gastrostomy – indications and outcome of our experience at
the Singapore General Hospital.
Singapore Med J.
2001;
42
460-465
MissingFormLabel
- 22
Yao M D, Rosenvinge E C, Groden von C et al.
Multiple endoscopic biopsies in research subjects: safety results from a National
Institutes of Health series.
Gastrointest Endosc.
2009;
69
906-910
MissingFormLabel
- 23
Anderson M A, Ben-Menachem T, Gan S I et al.
ASGE guideline: Management of antithrombotic agents for endoscopic procedures.
Gastrointest Endosc.
2009;
70
1060-1070
MissingFormLabel
- 24
Veitch A M, Baglin T P, Gershlick A H et al.
Guidelines for the management of anticoagulant and antiplatelet therapy in patients
undergoing endoscopic procedures.
Gut.
2008;
57
1322-1329
MissingFormLabel
- 25
Bini E J, Firoozi B, Choung R J et al.
Systematic evaluation of complications related to endoscopy in a training setting:
A prospective 30-day outcomes study.
Gastrointest Endosc.
2003;
57
816
MissingFormLabel
- 26
Hui A J, Wong R M, Ching J Y et al.
Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents:
analysis of 1657 cases.
Gastrointest Endosc.
2004;
59
44-48
MissingFormLabel
- 27
Kim H S, Kim T I, Kim W H et al.
Risk factors for immediate postpolypectomy bleeding of the colon: a multicenter study.
Am J Gastroenterol.
2006;
101
1333-1341
MissingFormLabel
- 28
Sorbi D, Norton I, Conio M et al.
Postpolypectomy lower GI bleeding: descriptive analysis.
Gastrointest Endosc.
2000;
51
690-696
MissingFormLabel
- 29
Hussain N, Alsulaiman R, Burtin P et al.
The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents:
a case-control study.
Aliment Pharmacol Ther.
2007;
25
579-584
MissingFormLabel
- 30
Oren A, Breumelhof R, Timmer R et al.
Abnormal clotting parameters before therapeutic ERCP: do they predict major bleeding?.
Eur J Gastroenterol Hepatol.
1999;
11
1093-1097
MissingFormLabel
- 31
Sawhney M S, Salfiti N, Nelson D B et al.
Risk factors for severe delayed postpolypectomy bleeding.
Endoscopy.
2008;
40
115-119
MissingFormLabel
- 32
Barkay O, Niv E, Santo E et al.
Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled
trial.
Surg Endosc.
2008;
22
1971-1976
MissingFormLabel
- 33
Rabenstein T, Fischer B, Wiessner V et al.
Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis.
Gastrointest Endosc.
2004;
59
606-613
MissingFormLabel
- 34
Singh M, Mehta N, Murthy U K et al.
Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel
therapy.
Gastrointest Endosc.
2010;
71
998-1005
MissingFormLabel
- 35
Hsieh Y H, Lin H J, Tseng G Y et al.
Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative
study.
Hepatogastroenterology.
2001;
48
1379-1382
MissingFormLabel
- 36
Friedland S, Sedehi D, Soetikno R.
Colonoscopic polypectomy in anticoagulated patients.
World J Gastroenterol.
2009;
15
1973-1976
MissingFormLabel
- 37
Hui C K, Lai K C, Yuen M F et al.
Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding?.
Aliment Pharmacol Ther.
2002;
16
929-936
MissingFormLabel
- 38
Gogarten W, Aken van H, Büttner J et al.
Regional anaesthesia and thromboembolism prophylaxis/anticoagulation – Revised recommendations
of the German Society of Anaesthsiology and Intensive Care Medicine.
Anästh Intensivmedizin.
2007;
48
S109-S124
MissingFormLabel
- 39
Gage B F, Waterman A D, Shannon W et al.
Validation of clinical classification schemes for predicting stroke: results from
the National Registry of Atrial Fibrillation.
JAMA.
2001;
285
2864-2870
MissingFormLabel
- 40
Blacker D J, Wijdicks E F, McClelland R L.
Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy.
Neurology.
2003;
61
964-968
MissingFormLabel
- 41
Berdague P, Boneu B, Soula P h et al.
Usefulness of low molecular weight heparins during post-operative period in mitral
mechanical valve replacement: clinical ischaemic and haemorrhagic complications in
110 cases (abstract).
Eur Heart J.
1998;
19 (Suppl)
534
MissingFormLabel
- 42
Fork F T, Lafolie P, Tóth E et al.
Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers.
A gastroscopic study.
Scand J Gastroenterol.
2000;
35
464-469
MissingFormLabel
- 43
Sørensen R, Hansen M L, Abildstrom S Z et al.
Risk of bleeding in patients with acute myocardial infarction treated with different
combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective
analysis of nationwide registry data.
Lancet.
2009;
374
1967-1974
MissingFormLabel
- 44
Foley P, Foley S, Kinnaird T et al.
Clinical review: gastrointestinal bleeding after percutaneous coronary intervention:
a deadly combination.
QJM.
2008;
101
425-433
MissingFormLabel
- 45
Chassot P G, Delabays A, Spahn D R.
Perioperative antiplatelet therapy: the case for continuing therapy in patients at
risk of myocardial infarction.
Brit J Anaesth.
2007;
99
316-328
MissingFormLabel
- 46
Collet J P, Montalescot G, Blanchet B et al.
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary
syndromes.
Circulation.
2004;
110
2361-2367
MissingFormLabel
- 47
Ho P, Peterson E D, Wang L et al.
Incidence of death and acute myocardial infarction associated with stopping Clopidogrel
after acute coronary syndrome.
JAMA.
2008;
299
532-539
MissingFormLabel
- 48
Moussa I D, Colombo A.
Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers,
reasons, and management recommendations.
Catheter Cardiovasc Interv.
2009;
74
1047-1054
MissingFormLabel
- 49
Cardiac Society of Australia and New Zealand .
Guidelines for the management of antiplatelet therapy in patients with coronary stents
undergoing non-cardiac surgery.
Heart Lung Cir.
2010;
19
2-10
MissingFormLabel
- 50
Patti G, Colonna G, Pasceri V et al.
Randomized trial of high loading dose of Clopidogrel for reduction of periprocedural
myocardial infarction in patients undergoing coronary intervention: results from the
ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty)
study.
Circulation.
2005;
111
2099-2106
MissingFormLabel
- 51 Altenhofen L, Heringer M, Blaschy S et al. Projekt wissenschaftliche Begleitung von Früherkennungs-Koloskopien in Deutschland. http://www.zi-berlin.de/koloskopie/downloads/Jahresbericht_2007_Berlin_Vers_1_1.pdf
MissingFormLabel
- 52
Bokemeyer B, Bock H, Hüppe D et al.
Screening colonoscopy for colorectal cancer prevention: results from a German online
registry on 269 000 cases.
Eur J Gastroenterol Hepatol.
2009;
21
650-655
MissingFormLabel
- 53
Becker R C, Scheiman J, Dauerman H L et al.
Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary
artery disease undergoing elective endoscopic gastrointestinal procedures.
Am J Gastroenterol.
2009;
104
2903-2917
MissingFormLabel
- 54
Cryer B.
Management of patients with high gastrointestinal risk on antiplatelet therapy.
Gastroenterol Clin N Am.
2009;
38
289-303
MissingFormLabel
Prof. Stefan Müller-Lissner
Abteilung Innere Medizin, Park-Klinik Weissensee
Schönstraße 80
13086 Berlin
Telefon: ++ 49/30/96 28 36 00
Fax: ++ 49/30/96 28 36 05
eMail: mueli@park-klinik.com